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Abstract: TRPC proteins form cation conducting channels regulated by different stimuli and are 
regulators of the cellular calcium homeostasis. TRPC are expressed in cardiac cells including cardiac 
fibroblasts (CFs) and have been implicated in the development of pathological cardiac remodeling 
including fibrosis. Using Ca2+ imaging and several compound TRPC knockout mouse lines we 
analyzed the involvement of TRPC proteins for the angiotensin II (AngII)-induced changes in Ca2+ 
homeostasis in CFs isolated from adult mice. Using qPCR we detected transcripts of all Trpc genes 
in CFs; Trpc1, Trpc3 and Trpc4 being the most abundant ones. We show that the AngII-induced Ca2+ 
entry but also Ca2+ release from intracellular stores are critically dependent on the density of CFs in 
culture and are inversely correlated with the expression of the myofibroblast marker α-smooth 
muscle actin. Our Ca2+ measurements depict that the AngII- and thrombin-induced Ca2+ transients, 
and the AngII-induced Ca2+ entry and Ca2+ release are not affected in CFs isolated from mice lacking 
all seven TRPC proteins (TRPC-hepta KO) compared to control cells. However, pre-incubation with 
GSK7975A (10 µM), which sufficiently inhibits CRAC channels in other cells, abolished AngII-
induced Ca2+ entry. Consequently, we conclude the dispensability of the TRPC channels for the 
acute neurohumoral Ca2+ signaling evoked by AngII in isolated CFs and suggest the contribution of 
members of the Orai channel family as molecular constituents responsible for this 
pathophysiologically important Ca2+ entry pathway. 
Keywords: TRPC channels; cardiac fibroblasts (CFs); Ca2+ release and Ca2+ entry; angiotensin II 
 
1. Introduction 
Remodeling processes comprising the activation of fibroblasts and the consequent changing in 
the extracellular matrix (ECM) composition are key processes during the development of different 
pathologies in several organs. Abnormal deposition of ECM proteins including collagens, or fibrosis 
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occurs for example during non-alcoholic fatty liver disease (NAFLD) [1,2] or pathological cardiac 
remodeling presented by the failing heart or after myocardial infarction [3,4]. 
Among the different cell types found in the heart, cardiac fibroblasts (CFs) which represent the 
big majority are important mediators regulating the secretion of growth factors with direct impact on 
cardiomyocyte function, cardiac hypertrophy development and ECM formation during both normal 
cardiac growth and pathological conditions [5,6]. The term “cardiac fibroblast” groups a 
heterogeneous population of cells with probably multiple origins and different functional, 
morphological and molecular profiles that are observed depending on the status of the heart [7,8]. In 
the last years an eminent increased effort to characterize such cells has been evident; for example, to 
define differences between populations of resident fibroblasts, activated fibroblasts and 
myofibroblasts, the last ones being prominent in ECM deposition, secretion and tissue contraction 
[9–11]. Recently, matrifibrocytes were described, which develop from myofibroblasts and persist in 
the scar after myocardial infarction giving structural support [12]. Therefore, a multiple 
characterization of fibroblasts models such as primary cultured cells is a necessary step to understand 
the biology behind fibroblast functioning and required to utilize them in the development of 
therapeutic strategies, for example for heart disease management [13]. 
In CFs, different ion channels and ion transport pathways are found, and Ca2+ entry pathways 
are important in CFs and are considered to contribute to the development of fibrosis. In CFs, Ca2+ 
entry pathways include receptor-operated Ca2+ entry (ROCE) channels and store-operated Ca2+ entry 
(SOCE) channels [14,15]. ROCE channels are engaged via G-Protein coupled receptor-mediated 
activation of the Phospholipase C (PLC) (i.e., downstream of angiotensin II -AngII-) and receptor 
tyrosine kinase-mediated activation of the PLC signaling. Both result in hydrolysis of 
phosphatidylinositol-4,5-bisphosphate (PIP2) with formation of the second messenger diacylglycerol 
(DAG) and inositol 1,4,5- trisphosphate (IP3) [16–18]. SOCE is activated in response to depletion of 
the Ca2+ concentration within the lumen of the endoplasmatic reticulum (ER) [16,19]. This can be 
achieved by agonist evoked generation of inositol 1,4,5-trisphosphate (IP3) and subsequent ER Ca2+ 
release through the IP3 receptor (InsP3R) or experimentally by thapsigargin, a specific inhibitor of the 
sarco-endoplasmatic reticulum Ca2+ATPase (SERCA), leading to passive depletion of ER Ca2+ stores. 
SOCE is mediated by channels activated by emptying of intracellular Ca2+ stores and the best 
characterized of these SOC channels are the Ca2+ release-activated Ca2+ channels (CRAC channels) 
[16]. Orai proteins form highly Ca2+ selective SOC channels [20–23] and three isoforms (Orai1, Orai2 
and Orai3) have been described [24,25]. However, the relative contribution of each of the three Orai 
proteins to endogenous SOC channels may differ between individual primary cells as revealed in 
different subsets of primary lymphocytes [26]. Ca2+ depletion is sensed by STIM proteins (STIM1 and 
STIM2) located in the sarcoplasmatic reticulum membrane [22,27]. After Ca2+ store depletion the 
conformation of STIM proteins changes, they oligomerize on the sarcoplasmatic reticulum’s surface 
and translocate to the plasma membrane at so called ER-PM junctions where STIM proteins are able 
to activate Orai proteins through direct contact [27–30]. AngII is a prominent effector regulating 
fibroblast cell functions including proliferation, migration and ECM deposition leading to 
development of fibrosis [3]. It has been shown that AngII treatment of rat CFs induces expression of 
the transforming growth factor β1 (TGF-β1) and engagement of the AngII-TGF-β1 axis stimulates 
collagen I expression and cardiomyocyte hypertrophy [31–33]. This concept was proven in an in vivo 
model with TGF-β1-deficient mice that do not develop cardiomyocyte hypertrophy after AngII 
stimulation [34]. The role of TGF-β1 in myocardial infarction and cardiac remodeling including 
fibrosis and its regulation through AngII signaling have also been a topic of reviews [35,36]. In 
addition to AngII receptors there are also other receptors reported in CFs that evoke Gq/11-PLC 
signaling such as PAR receptors activated by molecules like thrombin. PAR1 is the most abundant 
PAR receptor in rat CFs and mediates pro-fibrotic responses like α-SMA expression [37]. Another 
PAR receptor, PAR 4, which is expressed in murine CFs is functionally up-regulated under high 
glucose conditions linked to diabetes [38]. PAR 4 is also activated by AngII and other inflammatory 
mediators [39]. Stimulation with thrombin elicits Ca2+ transients in cardiac chick fibroblasts [40] and 
it was reported that thrombin-evoked Ca2+ signals are mediated by TRPCs in endothelial cells [41]. 
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All members of the TRPC (canonical) subgroup of the family of Transient Receptor Potential 
(TRP) channels can form receptor-operated cation channels mediating ROCE [17] or can be part of 
the store operated Ca2+ entry (SOCE). The TRPC subfamily comprises seven members in mammals 
(TRPC1 to 7). These channels exhibit six putative transmembrane domains with both C and N termini 
being intracellularly located and it is believed that TRP channels are assembled as homo- or hetero-
tetramers to form cation selective channels [42–44]. Recently, it was demonstrated via quantitative 
high-resolution mass spectrometry analysis using subtype specific antibodies that TRPC1, TRPC4, 
and TRPC5 form heteromultimers with each other but not with other TRP family members in the 
mouse brain and hippocampus [45]. Corresponding analyses in other tissues including the heart were 
not reported yet, although numerous studies reported their expression and function in 
cardiomyocytes but also in non-myocytes including cultured fibroblasts [46–52]. 
Regarding the role of TRPCs in CFs it was shown that in freshly isolated rat CFs non-selective 
cation currents triggered by stimulation of the C-type natriuretic peptide (CNP) receptors show 
characteristics of TRPC-mediated ion currents [53]. Some publications establish TRPC3 as an 
important regulator of fibroblast function and fibrosis development based on observations assuming 
the blockade of TRPC3 by channel blockers like Pyr-compounds - mainly Pyr3- or based on the 
analysis of global TRPC3-KO mice [54–56]. The structurally most closely related channel to TRPC3 is 
TRPC6 which has been reported as an important regulator of myofibroblast differentiation in CFs, 
including TGF-β1-mediated up-regulation of α-SMA and AngII-induced collagen expression [57–60]. 
TRPC6 should also contribute to the increase of intracellular Ca2+ concentration elicited by OAG (1-
Oleoyl-2-acetyl-sn-glycerol) in human ventricular fibroblasts [61]. In vivo inhibition of TRPC6 by BI-
749327 reduces cardiac fibrosis produced by pressure overload as well as fibrosis developed in a 
model of renal injury [62]. TRPC1/C4-DKO mice show reduced cardiac fibrosis development after 
pressure-overload as well as reduced expression of collagen genes after chronic neurohumoral 
stimulation with AngII [63]. 
In this study we used Ca2+ imaging in primarily isolated CFs from several TRPC-deficient mouse 
lines to determine the involvement of TRPC proteins for the AngII-induced Ca2+ release and Ca2+ 
entry in murine isolated adult CFs. We were able to detect transcripts from all seven TRPC in isolated 
fibroblasts and we show that the AngII-induced Ca2+ signals are critically dependent on cell culture 
density and are inversely correlated with the expression of the myofibroblast marker α-smooth 
muscle actin. We found that AngII-induced Ca2+ transients and the AngII-induced Ca2+ release and 
Ca2+ entry are not affected in CFs isolated from mice lacking all seven TRPC proteins compared to 
control cells; but, this Ca2+ entry pathway was inhibited by the CRAC blocker GSK7975A. Finally, we 
conclude the dispensability of the TRPC channels for the acute neurohumoral Ca2+ signaling evoked 
by AngII or thrombin in isolated CFs leading an open question for the molecular identities 
responsible for this complex response essential for fibroblast function. 
2. Materials and Methods 
2.1. Animal Experiments 
All animal procedures were approved and performed according to the regulations of the 
Regierungspräsidium Karlsruhe and the University of Heidelberg (T80/13, T87/14 and T85/15) and 
conform to the guidelines from Directive 2010/63/EU of the European Parliament on the protection 
of animals used for scientific purposes. The generation of TRPC1, TRPC2, TRPC3, TRPC4, TRPC5, 
TRPC6 and TRPC7 single knock-out (KO) mice was described previously [64–70]. TRPC compound 
KO mice, such as TRPC1/C4-Double KO (DKO), TRPC3/C6-DKO and TRPC-hepta KO 
(Trpc1/2/3/4/5/6/7–/–) mice were consecutively generated by crossing TRPC-single and TRPC-multiple 
KO mouse lines [71]. TRPC-KO mouse lines had a mixed 129SvEv/C57Bl6/N (TRPC-hepta KO) or 
129SvJ/C57Bl6/N (TRPC1/C4-DKO and TRPC3/C6-DKO) genetic background; offspring from the F1 
generation between 129SvJ and C57Bl6/N intercrosses were used as controls. Mice were maintained 
under specified pathogen-free conditions at the animal facility (IBF) of the Heidelberg Medical 
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Faculty in a 12-h light-dark cycle, and water and standard food (Rod18, LASvendi GmbH, Germany) 
were available to consume ad libitum. 
2.2. Isolation and Primary Culture of Cardiac Fibroblasts (CFs) 
To isolate CFs, the hearts from mice between 6–8 weeks old were isolated and digested by 
retrograde perfusion in a Langendorff apparatus as previously described [63,72]. A modified 
procedure is briefly described below. Mice were sacrificed by cervical dislocation; the hearts were 
quickly exposed via thoracotomy and 1–1.5 mL ice-cold modified Tyrode’s solution (TS) containing 
(in mM): 134 NaCl; 4 KCl; 1.2 MgSO4; 1.2 Na2HPO4; 10 HEPES; 11 glucose; pH 7.35 adjusted with 
NaOH, osmolarity 280–300 mOsm/kg and supplemented with 1000 U heparin, were slowly injected 
into both ventricles. Afterwards the hearts were removed and transferred to ice-cold TS and 
cannulated (20G cannula) via the aorta, attached to a Langendorff apparatus, and retrogradely 
perfused with carbogen (5% CO2, 95% O2 maintained at RT ~24 °C)-saturated TS containing 1000 
U/mL heparin, 200 µM EGTA and 10 mM 2,3-butanedione- monoxime for about 7 min (until the 
remaining blood was completely removed). The perfusion solution was then changed to constantly 
gassed (carbogen) and tempered (36 °C) TS containing a collagenase/ protease mixture (Liberase TM, 
Roche Applied Science, Pleasanton, CA, USA) at a final concentration of 133 µg/mL for 2–6 min 
(depending on size and age of the heart). The temperature of the perfusate was either maintained at 
35 °C or RT (24–25 °C) but no obvious differences were observed on the isolated cells. Thereafter, the 
ventricles were isolated from the atria, dissected and transferred to TS supplemented with 5 % bovine 
serum albumin (BSA), 12.5 µM Ca2Cl, and 1.4 ng/mL DNase I (Sigma-Aldrich Munich, Germany). 
The ventricles were cut into small pieces followed by gentle homogenization of the tissue using a cut 
and fire polished 1000 µL plastic tip. The suspension (final volume ~10 mL) was filtered through a 
nylon filter (pore size 150 µm, Sysmex, Norderstedt, Germany) and maintained for 10 min (37 °C) in 
the same solution for sedimentation; cardiomyocytes were mainly concentrated in the pellet. 
Fibroblasts remaining in the supernatant were transferred to a 15 mL tube and remaining 
cardiomyocytes were removed by a short centrifugation step of 48 × g (1 min, Megafuge 1.0 R, 
Heraeus, Hanau, Germany). The supernatant was transferred into a new tube and the cells were 
concentrated in a pellet by centrifugation (324 × g, 10 min); after removal of the remaining TS the cells 
were washed once with medium 199 (FG0615, Merck, Darmstadt, Germany). Finally, cells were 
gently resuspended in 5 mL of medium 199 supplemented with 2.5 % penicillin/streptomycin 
(151401222, Gibco, ThermoFisher Scientific, Waltham, MA), 50 µg/mL kanamycin (A1493, 
Applichem, Darmstadt, Germany), 0.1 µM insulin (I6634, Sigma-Aldrich) and 10 % FCS (10270-106, 
Gibco). Cells were seeded on a 25-cm2 culture flask (one heart per flask) and placed in a cell incubator 
(5 % CO2, 37 °C) for 2 h. Thereafter, the medium was changed to remove remaining tissue and not 
attached cells. After a period of 24 h of incubation the cells were de-attached from the culture flask 
by trypsin (1 % in DPBS and 0.2 mM EDTA) treatment (~3 min). After washing the cells with medium 
199 and determining the cell number, the harvested cells were resuspended in a desired 
concentration. To obtain cells on high cell density conditions (>300 cells/mm2) the CFs were 
resuspended at a concentration of 1000 cells/µL, then a drop of 10 µl from the cell suspension (small 
volume to ensure high density) was placed on a glass coverslips, the cells were let to attach for 1–2 h 
in the incubator; after the attachment period the medium was replenish (1–2 mL) and the cells were 
further cultured until its analysis. For low density cultures CFs were resuspended in 1.2 mL medium 
and the cells were seeded on glass coverslips (100–200 µL/well) where a silicone isolator (Grace Bio-
Labs, Sigma-Aldrich) with a free area of 100 mm2 was placed. After 2 h the medium was replenished 
and cells were cultured until analysis. For expression analysis via qPCR the cells were cultured in 
high density conditions (see above) on coverslips pre-coated with Extra Cellular Matrix (ECM Gel 
from Engelbreth-Holm-Swarm murine sarcoma, E1270, Sigma-Aldrich). After 6 days, CFs were 
washed with DPBS followed by detachment of cells with trypsin. After centrifugation (300 × g, 10 
min), the cell pellet was resuspended in DPBS, containing 0.1 % BSA, 25 mM HEPES and 1 mM EDTA. 
Finally, the supernatant was removed after centrifugation and the cell pellets were snap frozen in 
liquid nitrogen and stored at −80 °C until RNA isolation. 
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2.3. RNA isolation and qPCR Analysis 
RNA isolation from Langendorff heart-derived fibroblasts was performed using the Direct-Zol 
RNA MicroPrep (Zymo Research, Freiburg im Breisgau, Germany) including DNA digestion and 
following the instructions of the manufacturer. Integrity and quantity of the RNA samples were 
determined by microfluidic analysis (Bioanalyzer 2100, Agilent Technologies, Santa Clara, CA, USA) 
and fluorometry (qbit assay, ThermoFisher Scientific), respectively. cDNA synthesis from 700–1000 
ng of RNA was carried out using a SuperScript first-strand synthesis system for RT-PCR (SensiFAST 
BIO-65054, BIOLINE, London, UK). 30 ng cDNA from each sample were used as template. In brief, 
qPCR was performed with a Universal Probe Library (Roche) (probes and primers are listed in Table 
S1) by using Roche FastStart Essential DNA Probes MasterMix (Roche 06402682001) and detection on 
a Light Cycler96 (Roche). Thermal cycling conditions include: Initial denaturing at 95 °C for 600 s, 
followed by 40 cycles of amplification (each cycle: 10 s/95 °C, 30 s/60 °C). All PCR reactions were 
performed in duplicate and normalized to the expression of the house keeping genes H3F3A, AIP 
and CXXC1.The standard curve quantization method was used for gene expression measurements. 
Values are expressed as relative expression and calculated as follows: Relative Expression= (Mean E-
Cq/Mean EHKG-Cq)/((Mean EHKG/100+1)-Cq × 104), being E the efficiency, Cq the cycle of quantification and 
HKG refers to housekeeping genes. For visualization of qPCR products 10µL from the PCR reactions 
were run on 2 % agarose gels at 100 V during 20 min; images were obtained and digitalized with a 
GelDoc™ XR system (Bio-Rad, Feldkirchen, Germany). 
2.4. Immune Fluorescence Staining.  
Primary CFs isolated from WT mice (either C57BL6/N or the F1) were cultured on glass 
coverslips. Before cell fixation the samples were rinsed in cold PBS (in mM, 137 NaCl, 2.7 KCL, 8.1 
Na2HPO4, 1.8 KH2PO4, pH 7.4, sterile filtered). Cell fixation was done by incubation in 4 % 
Paraformaldehyde prepared in PBS over 10 min at 4°C and subsequently the cells were washed 2 × 5 
min by submerging them in cold PBS. The samples were transferred into pre-chilled acetone (−20 °C) 
for exactly 5 min (step omitted when CD31 was used) and washed for 5 min 3 × with cold PBS. To 
block unspecific binding, the samples were incubated for 1 h (RT) in 1 % BSA prepared in PBST (0. 
1% v/v Tween20 in PBS or only PBS for CD31) including 0.3 M glycine which reduces the background 
by binding to free aldehyde groups. Between 50–100 µL from the primary antibody solved in 1 % 
BSA (PBST or only PBS for CD31) were added and the cells were incubated at room temperature and 
protected from light in a humid chamber. The following primary antibodies were used: Anti-P4HB 
(11245-AP, Acris, Herford, Germany), anti-DDR2 (sc-7555, Santa-Cruz, Dallas, TX, USA), anti-CD31 
clone P2B1 (ab24590, abcam, Cambridge, UK) used as endothelial marker, anti-smooth muscle α2-
actin (ab15734, abcam), anti-αSMA clone 1A4 (A2547, Sigma-Aldrich) and anti-α-actinin clone EA-53 
(A7811, Sigma-Aldrich). After incubation with the primary antibody, three washing steps of 5 min 
each with cold PBS were done followed by the incubation with the secondary antibodies (Table S2) 
at room temperature and protected from light. The secondary antibody mixtures were decanted and 
three 5 min-washing steps with cold PBS were performed. To stain the nuclei the cells were incubated 
for 5 min with DAPI 1.5 µg/mL in PBS. Finally, the coverslip were mounted on glass slides using an 
anti-fade mounting medium (Vectashield, Linaris, Dossenheim, Germany or self-made solution: 6 g 
glycerin, 2.4 g Mowiol 4-88, 6 mL ddH2O, 12 mL Tris-HCl 0.2 M pH 8.5 and DABCO 25 mg/mL) and 
were stored at 4 °C protected from light until analysis. Concentration and incubation times for each 
antibody used are depicted in Table S2. As positive control for the selected markers freshly isolated 
mouse cardiomyocytes, freshly isolated ileum smooth muscle cells (iSMC) and mouse aortic 
endothelial cells (MAEC) were prepared as previously described [55,61,62]. Negative controls 
omitting the primary antibody were included and processed the same. For the fluorescence analysis 
two different setups were used. First, an AxioVert 200 M inverted microscope (Zeiss, Jena, Germany) 
equipped with a HXP120 fluorescence lamp (Kübler codix, Leistungselektronik JENA GmbH, Jena, 
Germany), a digital camera AxioCam MRm (Zeiss), filters (AHF analysentechnik AG, Tübingen, 
Germany) for FURA (DAPI), GFP (Alexa Fluor-488) and Alexa-594 was used. Alternatively an Axio 
Observer Z.1 microscope equipped with DG-4 light source (Sutter Instruments, Novato, CA, USA), 
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an AxioCam MRM camera (Zeiss) and, HC Basic (F26-510, DAPI), HC Basic TxRed (F26-518) and HC 
EGFP (F36-525) filter sets was used. Images were digitalized using the AxioVision v4.7.2 software 
(Zeiss). 
2.5. Calcium Imaging 
One day prior (at least 24 h before) to calcium measurements cells were changed to a medium 
without FCS that was replaced by to 0.01 % BSA (A7906, Sigma-Aldrich). Cells were incubated with 
5 µM fura-2 acetoxymethyl ester (dissolved in 20 % w/v Pluronic, F-127 Sigma-Aldrich in DMSO) for 
30 min at room temperature in a physiological solution that contained in mM: 134 NaCl, 4 KCl, 1.2 
MgSO4, 1.2 Na2HPO4, 2 CaCl2, 11 glucose and 10 HEPES. After incubation the cells were rinsed 3 
times with physiological solution and the glass coverslips were transferred into a measuring chamber 
(AttoFluor®, MolecularProbes, ThermoFisher Scientific, Waltham, MA). Changes in intracellular Ca2+ 
concentration were measured using an inverted microscope (Axio Observer-A1 or Axio Observer Z1, 
Zeiss) equipped with either a Monochromator (Polychrome V, Till Photonics, Planegg, Germany) or 
a monochromator-based imaging system consisting of a Lambda DG-4 Plus Light source (Sutter 
Instrument), a Filterset Fura 2 HC (Nr.: H76-521, AHF, Tübingen, Germany), a 20× objective (NA 0.75, 
Fluar, Zeiss) and a CCD camera (Axiocam MMR, Zeiss). Image acquisition and digitalization were 
done with the Physiology Module from the Axiovision 4.8.2 software (Zeiss). Fluorescence at 510 nm 
was measured during alternative excitation at 340 nm and 380 nm. The excitation and emission 
detection cycles were done every 5 s. After correction for the background fluorescence signals at both 
excitation wavelengths, the fluorescence ratio (F340/F380) was calculated and analyzed using 
OriginPro 2015G (OriginLab, Northampton, MA, USA). For Ca2+ measurements without extracellular 
Ca2+, CaCl2 was omitted from the physiological solution and was it replaced by EGTA as depicted on 
the figures. Perfusion and changing of the solutions was done by a gravimetric perfusion system 
coupled to a suction vacuum pump. 
2.6. Agonist and Blockers 
The following compounds were used: angiotensin II (Cat. Nr. A9525, Sigma-Aldrich), thrombin 
(Cat. Nr. T4648, Sigma-Aldrich), TGF-1 (Cat. Nr. 101-B1-001, R&D Systems/Biotechne, Wiesbaden, 
Germany), GSK7975A (2,6-difluoro-N-(1-(4-hydroxy-2-(trifluoromethyl)benzyl)-1H-pyrazol-3-
yl)benzamide; Cat. Nr. AOB4124, AOBIOUS Inc., Gloucester, MA, USA), SAR7334 (4-(((1R,2R)-2-((R)-
3-aminopiperidin-1-yl)-2,3-dihydro-1H-inden-1-yl)oxy)-3-chlorobenzonitrile, provided by Bayer 
Pharma AG, Leverkusen, Germany), T320722 (5-chloro-2-(4-methylpyridin-1-yl)-1H-benzo 
[D]imidazole, Cat.Nr. T320722, Sigma-Aldrich). In experiments where the TRPC- or CRAC-
antagonists were used CFs were pre-incubated for 10 min in TS solution containing the blockers 
which were also included in the solutions used during the Ca2+ imaging experiments. 
2.7. Statistical Analysis 
Data were analyzed and processed with Excel 2007 (Microsoft, Redmond, WA, USA) and 
OriginPro 2015G ver. 9.2.257 (OriginLab). Values are shown as mean ± standard error of the mean 
(SEM) except for Figure 1C where standard deviation (SD) is shown. Statistical significances were 
assumed when p < 0.05. p-values are depicted as *p < 0.05; **p < 0.01, ***p < 0.001. Statistical analysis 
was performed using the two-tailed unpaired Student’s t-test except in Figure 1C where a Kruskal-
Wallis test followed by Dunn’s test for multiple comparisons were performed due to differences in 
the variance among the groups. 
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3. Results 
3.1. Characterization of Primary Isolated Murine Cardiac Fibroblasts (CFs) 
To determine the role of TRPC channels for the angiotensin II-induced Ca2+ response in isolated 
primary murine CFs we first determined the conditions of cell culture and analysis using CFs 
obtained from adult wild type (WT) mice. For that purpose cells isolated by a Langendorff-based 
perfusion system and subjected to a pre-plating strategy were cultured in different cell densities and 
subsequently analyzed with respect to their Ca2+ homeostasis (Figure 1A). 
 
Figure 1. Characterization of primary isolated murine cardiac fibroblasts. (A) Isolated primary CFs 
from adult mice were cultured at high (>300 cells/mm2) and low density as depicted. Phase contrast 
images showing the typical morphology and confluence of cultured fibroblasts at several time points 
of the culture are included. (B) Immunocytochemical characterization of primary cultures of CFs 
using antibodies against α-actinin, α-smooth muscle (SM) actin, P4HB and CD31 (Bi) or additionally 
DDR2 (Bii) is shown. (C) Expression analysis by qPCR from Trpc channels in four independent (n = 4 
hearts) primary cultures of CFs. bp: base pair. *p < 0.05 depicted are according to Dunn’s post-hoc 
comparisons after Kruskal-Wallis. 
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As initial step in our analysis the cells were characterized by immunocytochemistry (Figure 1B). 
As markers for fibroblasts we used antibodies against the prolyl 4-hydroxylase (P4HB) and the 
discoidin domain-containing receptor 2 (DDR2), which are considered as specific markers for these 
cells [73,74]. In addition, we used anti-α-actinin as marker for cardiomyocytes, CD31 for endothelial 
cells and α-smooth muscle actin for smooth muscle cells or for myofibroblasts, and included a 
corresponding positive control for each of these markers: cardiomyocytes, mouse aortic endothelial 
cells and ileum smooth muscle cells. We observed that our cultured primary fibroblasts were positive 
for both P4HB and DDR2 but negative for CD31 and α-actinin as expected (Figure 1B). Regarding α-
smooth muscle actin the CFs were negative for this marker only when cultured in a density higher 
than 300 cells/mm2. When cultured on lower density conditions the cell staining was positive for α-
smooth muscle actin (Figures 1B, 2C–D and S1A). This means that CFs easily differentiate into a 
myofibroblast-like phenotype when they are seeded at low density. Using cultured fibroblasts we 
also quantified expression of the transcripts encoding the seven members of the TRPC ion channel 
family. We could detect expression of all seven TRPC members being Trpc1, Trpc3 and Trpc4 most 
prominently expressed and TRPC4 being significantly higher expressed compared to Trpc5 and Trpc6 
in CF cultures at day 7 after isolation (Figure 1C). 
3.2. Differential Changes in Intracellular Ca2+ Concentration in CFs Depending on the Density of the 
Culture 
To monitor changes in the intracellular Ca2+ concentration in CFs we used Fura-2 loaded cells. 
We performed two kinds of protocols: With the first protocol agonist-induced Ca2+ transients in the 
presence of extracellular Ca2+ [2 mM] were investigated (Figures 2A–B). With the second protocol the 
agonist-induced Ca2+ release from internal stores in the absence of extracellular Ca2+ and the 
subsequent agonist-induced Ca2+ entry in the presence of extracellular Ca2+ were analyzed (Figure 
2C–D). We observed that the AngII-induced Ca2+ transients were significantly larger when the cells 
were maintained on high density conditions (Figures 2A–B); in addition, the AngII-induced Ca2+ 
release from intracellular stores was also larger in cells kept in high density conditions and AngII-
induced Ca2+ entry was only measureable in CFs cultured in these conditions (Figures 2C–D). These 
observations correlate inversely with the expression of the α-smooth muscle actin (Figures 2C–D and 
S1A). Taken together, our observations lead to the conclusion that the cell density is an important 
component that defines the cell morphology, protein expression and agonist-induced Ca2+ signaling 
in primary cultures of CFs. Using the concept that the AngII-induced Ca2+ transients are more 
prominent under high density, we tested if TRPC1/C4 deletion could alter these responses; however, 
no differences were observed between WT and DKO-CFs after 4, 5 or 6 days in culture (Figure S1B). 
Additionally, we tested the Ca2+ transients evoked by different Thrombin concentrations (Figure S1C) 
and found also no differences between fibroblasts from WT and TRPC1/C4-DKO mice (Figure S1D). 
These observations indicate the dispensability of TRPC1/C4 in the acute Ca2+ signaling in isolated 
CFs. 
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Figure 2. Changes in intracellular Ca2+ concentration in cardiac fibroblasts depending on the density 
of the culture. (A–B) AngII-induced Ca2+ transients in primary CFs in the presence of 2 mM 
extracellular Ca2+. Cells were analyzed 5 days after isolation and cultivation at low (A) or high density 
(B). Fluorescence images of Fura-2 loaded cells are included. (C–D) AngII-induced Ca2+ release from 
internal stores and subsequent AngII-induced Ca2+ entry were analyzed in fibroblasts maintained at 
low (C) or high density (D) conditions. Additionally, the expression of α-SM-actin was analyzed on 
cells cultured on each cell density (upper panels). n = number of independent preparations (hearts). 
3.3. Effect of TRPC3/C6 Genetic Deletion or Its Pharmacological Inhibition with SAR7334 on the AngII-
Induced Ca2+ Release and Ca2+ Entry 
After defining that AngII-induced Ca2+ entry with a robust Ca2+ release is only observed in 
fibroblasts kept at high density and TRPC3 and TRPC6 being described as important regulators of 
fibroblast function [15,47,48,51], we studied the effect of genetic deletion of TRPC3/C6 proteins or its 
acute inhibition with the described TRPC3/C6/C7 blocker SAR7334 [75] on AngII-induced Ca2+ 
release and Ca2+ entry. The genetic deletion of both TRPC3 and TRPC6 did not affect Ca2+ release or 
Ca2+ entry induced by AngII in primary CFs. No difference between WT and TRPC3/C6-DKO CFs on 
the AngII-induced Ca2+ signaling were observed after 5 (Figure 3A) or 6 days (Figure S2A) in culture. 
Moreover, the acute blockage of TRPC3/C6/C7 channels by SAR7334 had no effect on the AngII-
induced Ca2+ release and Ca2+ entry in WT cells or in cells isolated from TRPC3/C6-DKO mice (Figures 
3B and S2B). These results indicate that there is no involvement of TRPC3/C6 proteins in the acute 
AngII-induced Ca2+ release and Ca2+ entry in primary fibroblasts and moreover that SAR7334 does 
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not have unspecific effects on AngII-induced Ca2+ release and Ca2+ entry in this cell system as no 
difference was observed between WT and TRPC3/C6-DKO CFs treated with the blocker. 
Because it was recently shown that expression of Trpc6 is upregulated by TGF-β treatment and 
that TRPC6 channels play a role in TGF-β induced myofibroblast differentiation [58] we pre-
incubated CFs with TGF-β to determine the effect of TGF-β treatment on Ca2+ signaling. After TGF-β 
pre-treatment we observed an increased expression of α-smooth muscle actin even though the cells 
were kept on high density conditions during 5 or 6 days in culture (Figures 3C and S2C). In line with 
our findings in Figure 2, we observed in WT cells that the increased α-smooth muscle actin expression 
was inversely correlated with the magnitude of the AngII-induced Ca2+ release and Ca2+ entry in adult 
CFs (Figure 3C). This points out that TGF-β leads to differentiation of our cultured fibroblasts to a 
more myofibroblast-like phenotype and significantly reduces the AngII-induced Ca2+ signaling like 
it was observed under low-density conditions. 
 
Figure 3. AngII-induced Ca2+ release and Ca2+ entry in the absence of TRPC3/C6 or after TGF-β pre-
treatment. (A) AngII-induced Ca2+ release and Ca2+ entry in primary CFs from WT (black) and 
TRPC3/C6-DKO (red) mice. Ca2+ release was measured in the absence of extracellular Ca2+ (300 µM 
EGTA) and Ca2+ entry was monitored in the presence of 2 mM extracellular Ca2+. Left panels: Original 
traces and right panels: Mean values from three independent preparations (hearts). (B) Measurements 
performed as in (A) but in cells pre-incubated (10 min) with the TRPC3/C6/C7 antagonist SAR7334 (1 
µM). (C) AngII-induced Ca2+ release and Ca2+ entry in primary CFs from WT mice cultivated in the 
presence of 10 ng/mL TGF-β (green) or under control conditions (black). Left panel: α-actin smooth 
muscle staining after TGF-β treatment, middle panels: Original traces from Ca2+ measurements and 
right panels: Mean values from 3 independent preparations. n = number of independent preparations 
(hearts). All cells were analyzed 5 days after isolation and were cultured at high density. *p < 0.05 
according to the unpaired Student’s t-test. 
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3.4. Dispensability of All TRPC Proteins for the Acute Ca2+ Release and Ca2+ Entry Induced by AngII in 
Cardiac Fibroblasts 
We could show that members of two subgroups of the TRPC family, TRPC1/C4 and TRPC3/C6, 
were not involved in the acute AngII-induced changes in intracellular Ca2+ concentration in primary 
fibroblasts. 
To continue with our study, we additionally tested if any other member of the TRPC subgroup 
such as e.g., TRPC4/C5 could be part of the AngII-induced Ca2+ signaling in CFs. For this purpose, 
we took advantage of the recently described TRPC blocker T320722 [76] with relative specificity for 
TRPC4 (IC50 4.1 µM) and TRPC5 (IC50 3.1 µM) compared to TRPC3 (IC50 30.4 µM) and TRPC6 (IC50 
57.1 µM). Pre-treatment (10 min) of CFs with 10 µM T320722 had no effect on the AngII-induced Ca2+ 
release but it was able to significantly reduce the AngII-induced Ca2+ entry in WT cells (Figure S3A–
B). To further test this observations and because the deletion of one TRPC protein might be 
compensated by the upregulation of other TRPCs [69] we decided to analyze the Ca2+ signaling in 
fibroblasts in which none of the TRPC channel proteins is expressed using cells isolated from TRPC-
hepta KO (Trpc1/2/3/4/5/6/7–/–) mice [71]. The acute Ca2+ transients evoked either by AngII or by 
thrombin were not different between WT and TRPC-hepta-KO CFs after 5 or 6 days in culture 
(Figures 4A–B and S4A–B). Moreover, in the absence of all TRPC proteins neither the acute AngII-
evoked Ca2+ release nor the AngII-evoked Ca2+ entry were impaired in comparison with WT control 
cells (Figures 4C and S4C). Together these results indicate that deletion of all TRPC-proteins in CFs 
does not impair the acute AngII-induced Ca2+ release and entry in isolated CFs. To further explore 
other possible molecular entities responsible for the acute AngII-induced Ca2+ entry in CFs, we 
performed experiments in CFs from WT mice in the presence of the CRAC inhibitor GSK7975A [77] 
that was characterized in pancreatic acinar cells and mast cells [78,79]. Pre-incubation with the CRAC 
blocker was able to completely abolish the Ca2+ entry initiated by 100 nM AngII stimulation (Figure 
4D), indicating the involvement of proteins from the Orai family in this Ca2+ entry pathway. 
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Figure 4. AngII-induced Ca2+ release and Ca2+ entry in cardiac fibroblasts in the absence of all seven 
TRPC proteins. (A) AngII- and (B) thrombin-induced Ca2+ transients in primary CFs from WT (black) 
and TRPC-hepta (Trpc1/2/3/4/5/6/7–/–) KO (red) mice. Ca2+ transients were measured in the presence of 
2 mM extracellular Ca2+. Left panels: Original traces and right panels: Mean values of three 
independent preparations (hearts). (C) AngII-induced Ca2+ release and Ca2+ entry in primary CFs from 
WT (black) and TRPC-hepta KO (red) mice. Ca2+ release was measured in the absence of extracellular 
Ca2+ (300 µM EGTA) and Ca2+ entry was monitored in the in the presence of 2 mM extracellular Ca2+. 
Left panels: Original traces and right panels: Mean values of three independent preparations. (D) The 
effect of the CRAC blocker (10 µM) GSK7975A on the AngII-induced Ca2+ release was analyzed in 
CFs from WT mice like in (C). Left panels: Original traces and right panels: Mean values of three 
independent preparations. n = number of independent preparations (hearts). All cells were analyzed 
5 days after isolation and were cultured at high density. *p < 0.05 and **p < 0.01 according to the 
unpaired Student’s t-test. 
4. Discussion 
There are several reports analyzing the role of TRPC proteins in cardiac fibroblasts (CFs) and in 
fibrosis development using TRPC antagonist, siRNA or shRNA; however, the causal contribution of 
TRPC isoforms for Ca2+ entry following stimulation with neurohumoral agonists relevant during 
development of cardiac remodeling in primary cardiac fibroblast isolated from TRPC-KO mice has 
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not been studied so far. In this study we therefore aimed to assess the causal contribution of TRPC 
proteins for Ca2+ entry following acute AngII application by comparative analysis of primary isolated 
CFs from several Trpc-deficient mouse models and WT controls. We showed that CFs isolated from 
global TRPC-hepta KO (Trpc1/2/3/4/5/6/7–/–) mice exhibit no impairment in AngII-induced Ca2+ entry 
nor Ca2+ release. 
To define the CF cell model used in this study we could prove a high homogeneity of our 
cultured cell population by positive immunostaining for the established CF-specific markers P4HB 
and DDR2 that was comparable with findings from other studies using similar approaches [74,80]. 
We avoided the use of the frequently used marker vimentin because it is also expressed in endothelial 
cells as well as in macrophages [73,80]. Comparison of two different culture conditions that we 
defined as low and high density, showed that a significant AngII-evoked Ca2+ entry was only 
observed at the increased cell density >300 cells/mm2 and that the Ca2+ release from intracellular stores 
was largely increased under high density condition. When the maximal peaks of the Ca2+ signals of 
the Ca2+ release and the Ca2+ entry are compared, the maximum peak of the Ca2+ entry is much lower 
than the one from the Ca2+ release. However, the Ca2+ release signals decay much faster in comparison 
to the Ca2+ entry; the Ca2+ entry is maintained elevated at least over minutes and it could account for 
higher Ca2+ concentrations over time triggering specific transcriptional programs and/or extracellular 
matrix production. Obviously, one or more steps in the signaling cascade triggered by AngII in CFs 
are enhanced under these high-density conditions. In addition, the magnitude of the Ca2+ signals 
induced by AngII is inversely correlated with the expression of the myofibroblast marker α-SMA. 
These correlation between Ca2+ signaling and cell density is not surprising due to published 
observations e.g., from endothelial cells where the importance of cell to cell contact for Ca2+ signaling 
was shown [81]. Defining and characterizing the cell culture conditions is an essential prerequisite to 
obtain reliable and reproducible experimental results in primary cells, and not only for the analysis 
of Ca2+ signaling. For example, changes in the starvation conditions, which were also optimized in 
our approach in CFs, have profound effects on the secretome of human prostatic stromal 
myofibroblasts and other cell types [82]. Despite that we did not look to the impact of the culture 
substrate on the Ca2+ signaling, this is another important variable determining the responses in 
primary cells; different culture substrates have significant effects on expression profiles as revealed 
by a transcriptome analysis from human dermal fibroblasts cells [83]. 
With our established protocol to culture and measure the AngII-induced Ca2+ release and Ca2+ 
entry, we first examined the expression of the TRPC channels and found transcripts from all seven 
Trpc genes with Trpc1, Trpc3 and Trpc4 being most abundant. Since it has been reported that TRPC3 
and TRPC6 are involved in fibroblasts function we first analyzed CFs from TRPC3/C6-DKO mice, to 
also circumvent possible compensation of TRPC6 in TRPC3-KOs as described [69]. We observed no 
alterations in AngII-induced Ca2+ entry or Ca2+ release compared to WT CFs. In addition, the 
TRPC3/C6/C7 blocker SAR7334 [75] elicited no changes in the Ca2+ responses. Based on our results 
obtained with this TRPC3/C6/C7 channel inhibitor it can be assumed that also TRPC7 has no essential 
role in the AngII-induced Ca2+ signals, because the acute blockage of all three channels (in WT cells) 
or the genetic inhibition of TRPC3/C6 plus pharmacological inhibition of TRPC7 (TRPC3/C6-DKO 
cells) did not affect the Ca2+ responses. In contrast to our results, it is published that targeting TRPC3 
channels by pharmacological inhibition using Pyr3 in cardiac fibroblast from adult rats is able to blunt 
AngII-induced Ca2+ entry and α-SMA expression [54]. Moreover, in in vivo fibrosis models it was 
shown that Pyr3 treatment reduces the increase in proliferation and α-SMA expression observed in 
left atrial fibroblasts from an atrial fibrillation model in dogs [54], the cardiac fibrosis and expression 
of fibrosis associated genes after pressure overload, and the TGF-β-induced CTGF and αSMA 
expression in human fibroblasts [55]. In line with these observations another Pyr compound, Pyr10, 
prevents myocardial fibrosis in a hypertension model [56]. Discrepancies between our study and 
published data can be accounted to the fibroblast’s origin (mouse, human or rat) or to the culture 
conditions. Unfortunately, in the in vivo studies published with TRPC3-KO mice no experiments 
with isolated CFs and no Ca2+ imaging experiments were reported. Remarkably, both Pyr compounds 
also block Orai1-mediated store-operated Ca2+ currents, with Pyr10 being more selective for TRPC3 
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(Pyr3: EC50 ROCE-TRPC3 0.54 µM and EC50 SOCE 0.54 µM; Pyr10 EC50 ROCE-TRPC3 0.72 µM and 
EC50 SOCE 13.08 µM) [84]. Furthermore, inhibition by siRNA of Orai1 or STIM1 in rat CFs reduces 
the AngII-induced Ca2+ entry, as well as the AngII-induced increase in expression of α-SMA, CTGF 
and Fibronectin [85]. These results are in accordance with our observations with the CRAC blocker 
GSK7975A that completely inhibited the AngII-induced Ca2+ entry. TRPC6 is regarded as an 
important regulator of fibroblasts function especially in terms of myofibroblast differentiation [57,58]. 
Approaches down-regulating TRPC6 expression showed reduction in the TGF-β1-mediated up-
regulation of α-SMA in human CFs from the right ventricle [59], reduction in the AngII-induced 
increase in collagen expression in rat CFs [60] and reduction in the OAG (DAG analogue)-induced 
elevation of Ca2+concentration in human ventricular fibroblasts [61]. One can assume that AngII-
evoked activation of Gq-coupled receptors and downstream signaling implicates DAG formation 
which can directly activate TRPC6-containing channels [86]; however, in TRPC3/C6-DKO the AngII-
induced Ca2+ signaling was not impaired, but ROCE induced by AngII following siRNA-mediated 
knock down of TRPC6 was not analyzed in the study from Ikeda and co-workers [61]. In contrast to 
our observations Ikeda and co-workers also showed that treatment with TGF-β enhanced the AngII-
induced Ca2+ entry, but using a 100-fold higher AngII concentration in human cells. In vivo evidence 
for the role of TRPC6 during fibrosis development comes from observations using TRPC6-KO mice. 
TRPC6-deficient dermal fibroblasts isolated from TRPC6-KO mice are refractory to TGF-β and AngII-
induced transdifferentiation (58); similar to that study we also observed that TGF-β treatment leads 
to a differentiation of the CFs to myofibroblasts with increased expression of α-SMA [58]. TRPC6-KO 
mice show impaired dermal and cardiac wound healing [58]. In that study the Ca2+ entry in CFs 
produced by inhibiting the Sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) was 
enhanced by TGF-β or AngII treatment and it was attributed to increased TRPC6 expression. In our 
experiments the Ca2+ entry after TGF-β pre-treatment was reduced in WT CFs and it was not different 
in the absence or pharmacological inhibition of TRPC6. Moreover, in primary murine lung fibroblasts 
AngII treatment does not affect TRPC6 levels whereas TGF-β changes TRPC6 expression levels [87]. 
Those differences can most likely be attributed to cell origin, cell culture conditions and/or different 
Ca2+ entry mechanism between the entry evoked by AngII or by SERCA blockage. Inhibition of 
TRPC6 by BI-749327 was shown to reduce cardiac fibrosis produced by pressure overload as well as 
fibrosis developed in a model of renal injury [62]; however, this blocker has not been validated in 
TRPC6-deficient cells or regarding its specificity on TRPC vs. its action on channels composed of Orai 
proteins. Beyond TRPC3 and TRPC6 we also analyzed with our experiments in TRPC-hepta KO and 
TRPC1/C4-DKO CFs the contribution of TRPC1 proteins to the AngII-induced Ca2+ signaling. Other 
groups also attempted to determine the activity of TRPC1 in right atrial human fibroblasts; however, 
the treatment with siRNAs against TRPC1 did not alter Ca2+ influx that was evoked in these 
fibroblasts by application of a bath solution containing 20 mM Ca2+ [88].  
The fact that we observed no differences in acute AngII-evoked Ca2+ signaling in the absence of 
both TRPC3/C6, and even in the absence of all seven TRPC proteins in CFs does not completely 
preclude that these TRPC proteins might be involved in the regulation of fibrosis-related gene 
expression in CFs. It is possible that conformational changes and signaling mediated thereby 
independent from ionic signaling conveyed by a channel protein can also play a role in stimulating 
transcription [89]. Along these lines it was recently shown that TRPC6 proteins are signaling via 
interaction with calpain independent of their channel function [90].  
Other candidates outside the TRPC group that could mediate the AngII-induced ROCE are 
found in other TRP subfamilies like TRPV, TRPM or TRPA, therefore below we discuss their 
implications in CFs functioning and fibrosis. For several TRP proteins different mechanisms for their 
involvement in fibroblast function and fibrosis development have been proposed. In CFs from TRPV1 
over-expressing mice the sustained Ca2+ rise provoked by capsaicin is enhanced; additionally, in those 
mice the Isoproterenol-induced cardiac fibrosis and cardiac hypertrophy in vivo are reduced [91]. In 
vitro, the AngII-induced proliferation of CFs is reduced by capsaicin in cells from WT but not from 
TRPV1-deficient mice [92]. In rats, the TRPV3 activator Carvacrol is capable to increase the fibrosis 
produced by aortic banding and it potentiates the AngII-induced increase in Ca2+ concentration as 
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well as the in vitro proliferation of CFs. In contrast, treatment with siRNA directed against TRPV3 
reduces the AngII-induced collagen expression [93]. Another TRPV channel, TRPV4, which 
determines myofibroblast differentiation and fibrosis in the lung [94], was also shown to mediate 
TGF-β1-induced differentiation of CFs into myofibroblasts [95]. The TRPV4-specific antagonist 
AB159908 as well as siRNA knockdown of TRPV4 significantly inhibit TGF-β1-induced 
differentiation as measured by incorporation of α-SMA into stress fibers of TGF-β1 treated fibroblasts. 
TGF-β1 treated fibroblasts exhibit enhanced TRPV4 expression and TRPV4-mediated calcium influx 
in CFs compared to untreated controls [95]. Stimulation of murine CFs isolated from WT mice with 
the TRPV4 agonist GSK-1016790A results in a significant Ca2+ rise, but this response is entirely absent 
in CFs from TRPV4-KO mice indicating that TRPV4 is functionally active in these CFs [96] and could 
be another candidate for the AngII-induced Ca2+ signaling. However, the role of TRPV4 for Ca2+ entry 
in CFs triggered by neurohumorally acting agonist has not been reported yet. 
A hypoxia-evoked cation current was described in cultured primary fibroblasts from adult rat 
hearts and siRNA against TRPM2 prevented the development of such current [97]. H2O2 induces a 
higher Ca2+ elevation in hypoxia-exposed adult rat CFs compared to normoxia-exposed cells, which 
was also attributed to TRPM2 [97]. In addition, TRPM7-like currents have been characterized in CFs 
from different species including mouse, human and rat [88,98–100]. Using also hypoxia as stimulus, 
it was proposed that the increased TRPM7 expression and activity in rat CFs during hypoxia is 
blocked by astragaloside-IV (most active component of Chinese sp. Astragalus), and that its inhibition 
by siRNA prevents fibrotic features in NIH-3T3 mouse fibroblasts [101]. Additionally, in rat CFs H2O2 
and AngII also are able to provoke a sustained increase in the intracellular Ca2+ and elevated 
expression of fibrogenic growth factors (e.g., α-SMA, TGF-β1) that were either blunted or reduced in 
fibroblasts in which TRPM7 was silenced via shRNA [102]. In human right atrial fibroblasts similar 
results were observed. Knockdown of Trpm7 mRNA with shRNA treatment reduces TGF-β1-induced 
differentiation and proliferation [88]. Using neonatal rat CFs and siRNA-mediated knockdown of 
TRPM7 it was recently proposed that TRPM7 regulates fibrotic features through the microRNA-135a 
[100]. Using macrophages from mice with deletion of the TRPM7-kinase domain it was revealed that 
such cells are able to induce a fibrotic phenotype (i.e., increased TGF-β) in CFs from WT mice and 
interestingly this effect was prevented by MgCl2 treatment [103]. These results lead to the conclusion 
that TRPM7 channels in other cells than CFs might play a role in fibrosis development. TRPA1, the 
only member of the TRPA group, has also been studied in fibroblasts. In primary human ventricular 
CFs methylglyoxal provokes a sustained increase in the intracellular Ca2+ concentration that is largely 
reduced by treatment with HC030031, a selective TRPA1 antagonist or by TRPA1 knockdown using 
siRNA [104]. In CFs from TRPA1-deficient mice the transdifferentiation evoked by TGF-β is strongly 
reduced; in vivo, cardiac fibrosis is reduced in TRPA1-KO mice after myocardial infarction but is 
increased in WT mice treated with the TRPA1 agonist cinnamaldehyde [105]. However, it remains 
still unclear whether development of cardiac fibrosis in these experiments is mediated by TRPA1 
channels present in CFs or other cell types. 
A main general limitation in studies about the role of TRPC channels for complex in vivo 
phenotypes and associated cellular mechanisms is the use of global KO mice. Global deletion of TRPC 
proteins during early development might evoke mechanisms and pathways that compensate for the 
loss of TRPC-containing channels. Furthermore, differences in processes depending on cell-cell 
interactions including Ca2+ signaling might occur. For example, TRPC1/C4-DKO mice show reduced 
development of cardiac fibrosis after pressure-overload as well as reduced expression of collagen 
genes after chronic neurohumoral stimulation with AngII most likely due to a reduced background 
Ca2+ entry in cardiomyocytes [63]. Nevertheless, this phenotype might also rely on TRPC1/C4 activity 
in other cells, particular cardiac non-myocytes, or depend on an in vivo cross-talk between 
cardiomyocytes and non-myocyte cells in the heart. However, the present study reduces the 
likelihood that AngII-triggered Ca2+ dependent processes in CFs, such as expression of fibrogenic 
growth factors and development of tissue fibrosis, are mediated by channels composed of TRPC 
proteins. To circumvent such problems and to address such questions the use of new conditional Trpc 
alleles (i.e., TRPC1/C4) that allow for a cell type-specific deletion of selective TRPC proteins would 
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be a promising approach. Nonetheless, such approaches can be challenging in CFs due to the 
diversity of CFs found in the healthy heart and during disease progression [11]. Alternatively the 
acute inhibition of TRPC channels by inhibitors might be used as an experimental setup to study Ca2+ 
homeostasis in isolated cells such as CFs. Here we observed that the TRPC blocker (T320722) reduces 
the AngII-induced Ca2+ entry; however, our interpretation in light of the observation from TRPC-
deficient cardiac fibroblasts is that such effect is more likely due to unspecific effects of that 
compound rather than the inhibition of a TRPC4/C5-mediated Ca2+ entry. Recently, an inhibitor of 
TRPC4- and TRPC5-homomeric channels as well TRPC1/TRPC4- and TRPC1/TRPC5-heteromeric 
channels has been developed [106,107]. This blocker (compound C31 or pico145) is highly potent (IC50 
in the picomolar range) and specific within the TRP channel family. However, its effectiveness in 
primary cells and in vivo has not yet been demonstrated. Apart from C31, other TRPC channel 
blockers such as ML204 and recent new derivates of C31 such as A54 [108] or AM237 [109] were 
reported, but have not yet been tested in primary cells or even CFs. 
Taken together, our results reveal the dispensability of TRPC proteins for the acute AngII-
induced Ca2+ signaling in isolated adult murine CFs. Furthermore, they prove the importance of cell 
density for intracellular Ca2+ homeostasis and transdifferentiation. CFs cultured at low density show 
markedly increased expression of the myofibroblast-marker α-SMA. Our work suggests that other 
Ca2+ conducting channels such as TRPV4, TRPM2, TRPM7 or members of the ORAI family of Ca2+ 
channels may mediate Ca2+ entry following activation of AngII-induced signaling cascades in CFs. 
Finally, by using the CRAC inhibitor GSK7975A we could show an important contribution of CRAC 
channels to the AngII-evoked Ca2+ signaling in cardiac fibroblasts.  
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WT  (black) and TRPC1/C4‐DKO  (red) mice. Ca2+  transients were measured  in  the presence of 2mM 
extracellular Ca2+. Left panels  show  original  traces  and  right panels  show  the mean value  of  three 
independent preparations (hearts); cells were analyzed after 4 (upper panels), 5 (middle panels) or 6 
days  (lower  panels)  of  isolation  and  were  cultured  at  high  density.  (C)  Ca2+  transients  in  WT 
fibroblasts induced by different concentrations of Thrombin. (D) Thrombin‐induced Ca2+ transients in 
primary  cardiac  fibroblasts  from WT  (black)  and  TRPC1/C4‐DKO  (red) mice. Ca2+  transients were 
measured  in the  in  the presence of 2mM extracellular Ca2+.; cells were analyzed after 4 days  (left), 5 
days  (middle panel) or 6 days  (right panel) of  isolation and cultured at high density. n= number of 
independent preparations (hearts). 
 
Figure S2. AngII‐induced Ca2+  release and entry  in  the absence of TRPC3/C6 or after TGF‐β pre‐
treatment.  (A) AngII‐induced Ca2+  release/entry  in primary cardiac  fibroblasts  from WT  (black) and 
TRPC3/C6‐DKO  (red) mice. Ca2+  release was measured  in  the  absence of  extracellular Ca2+  (300μM 
EGTA) and Ca2+  entry was monitored  in  the  in  the presence of 2mM  extracellular Ca2+. Left panels 
show original traces and right panels show the mean value of three independent preparations (hearts); 
cells were  analyzed  after  6  days  of  isolation  and  cultured  at  high  density.  (B)  Similar  to  (A)  but 
analysis from AngII‐induced Ca2+ entry/release in cells pre‐incubated (10min) with the TRPC3/C6/C7 
antagonist SAR7334 (1μM). (C) AngII‐induced Ca2+ release/entry  in primary cardiac fibroblasts from 
WT mice  cultivated  in  the presence of  10ng/ml TGF‐β  (green) or  in  control  conditions  (black). Left 



































Figure S4. AngII‐induced Ca2+ release and entry  in cardiac fibroblasts  in  the absence of all seven 
TRPC proteins.  (A) AngII‐ and  (B)  thrombin‐induced Ca2+  transients  in primary  cardiac  fibroblasts 
from WT (black) and TRPC‐hepta KO (red) mice. Ca2+ transients were measured in the in the presence 
of 2mM extracellular Ca2+. Left panels show original traces and right panels show the mean value of 
three  independent  preparations  (hearts).  (C)  AngII‐induced  Ca2+  release/entry  in  primary  cardiac 
fibroblasts from WT (black) and TRPC‐hepta KO (red) mice. Ca2+ release was measured in the absence 
of  extracellular Ca2+  (300μM EGTA)  and Ca2+  entry was monitored  in  the  in  the presence  of  2mM 
















































anti-P4HB anti-DDR2 anti-α-actinin anti-α-SM actin anti-CD31 
positive control fibroblasts fibroblasts cardiomyocytes iSMC MAEC
acetone permeabilization yes yes yes yes no
blocking 1% BSA in PBST 1% BSA in PBST 1% BSA in PBST 1% BSA in PBST 1% BSA in PBS
concentration 1µg/ml (in PBST) 1µg/ml (in PBST) 150µg/ml (in PBST) 10µg/ml (in PBST) 10µg/ml (in PBS)
incubation time 1h 1h 2h 2h 2h
secondary antibody anti-rabbit AlexaF488 anti-goat FITC anti-mouse AlexaF 594 anti-rabbit AlexaF488 anti-mouse AlexaF 594
2nd-ab provider Invitrogen (A11008) Sigma-Aldrich (F9012) Invitrogen (A11005) Invitrogen (A11008) Invitrogen (A11005)
2nd-ab dilution 1:1000 (in PBST) 1:200 (in PBST) 1:200 (in PBST) 1:200 (in PBST) 1:200 (in PBS)
2nd-ab incubation time 1h 1h 1h 1h 1h
